Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

France and Australia double Global Fund contributions:

This article was originally published in Clinica

Executive Summary

France and Australia are among the latest countries to answer calls from the Global Fund to Fight AIDS, Malaria and Tuberculosis for the world's wealthier countries to increase their contributions. France has pledged to "significantly increase" its contributions in 2006 rising to Euro300m (US$376m) by 2007 - thereby doubling the amount it contributed in each of 2004 and 2005. Australia too has pledged to double its commitment, allocating a further Aus$50m (US$39m) over three years. The pledges come ahead of last week's so-called replenishment conference in Rome. The event will seek to drum up international support for the organisation in the run-up to a final conference in London in September 2005, as it faces challenging funding targets. Current commitments stand at US$2.3bn in 2005, US$3.5bn in 2006 and US$3.6bn in 2007.

You may also be interested in...



Pfizer’s US Rituximab Launched At A 24% Discount

Pfizer has launched its Ruxience rituximab biosimilar in the US at a 24% discount to the wholesale acquisition cost of the Rituxan original. The firm has also revealed that when it launches its Trazimera trastuzumab biosimilar in mid-February, it will be at a 22% discount to the Herceptin brand’s WAC.

Teva Leapfrogs Mylan And Sandoz On Linaclotide

A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.

Tecentriq Disappoints In Post-Surgery Bladder Cancer

Failure is a knock-back for the blockbuster product, but Tecentriq has many more opportunities for trial success in 2020.

Topics

UsernamePublicRestriction

Register

MT055524

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel